The effect of the drug Brincidofovir

Brincidofovir otherwise popularly known as Tembexa Brincidofovir is indicated for the treatment of human smallpox caused by the variola virus. The drug is used for adult and pediatric patients, including infants .

Brincidofovir has the main ingredient cidofovir. Brincidofovir is an orthopoxvirus nucleotide analog DNA polymerase inhibitor and a nucleotide analog cidofovir lipid conjugate. It is indicated for the treatment of human smallpox caused by the variola virus in adult and pediatric patients, including infants.
Note: Based on animal studies showing that efficacy may be reduced when administered to immunocompromised patients.

How to use: The drug is prepared in the form of tablets and oral suspension, so the drug is taken orally. Brincidofovir is best absorbed on an empty stomach or with a low-fat meal.
Dosage: Tembexa is an oral antiviral drug that is available as a 100 mg tablet and 10 mg/mL oral suspension to be administered once weekly for a treatment period of two weeks. For patients with kidney failure or liver failure may not need to adjust the dose of the drug, apply the same dosage as normal people.
Contraindications: Not indicated for use in diseases other than human smallpox May increase the risk of death if used for a long time and in excess of the recommended dosage.

The most common side effects include diarrhea, nausea, vomiting, and abdominal pain. Uncommon side effects include increased serum creatinine, increased ALT, increased AST, peripheral edema, decreased appetite, muscle weakness, rash.

Increased liver transaminases and Bilirubin: May cause elevation of serum transaminases (ALT or AST) and serum bilirubin. Therefore, patients need to monitor liver test parameters before, during and after treatment with Brincidofovir.
Diarrhea and gastrointestinal side effects: Patients may experience diarrhea and other gastrointestinal side effects including nausea, vomiting, and abdominal pain. Therefore, patients need to monitor their health and if they experience severe reactions, they should contact their doctor or medical center for supportive care and if necessary.
Concomitant use with related products: Tembexa should not be used concomitantly with intravenous cidofovir.
Increased carcinogenicity: Tembexa is considered to be a probable human carcinogen.
Male infertility: Based on testicular toxicity in animal studies, Tembexa may impair fertility.
For pregnant women: Tembexa can harm an unborn baby when administered to a pregnant woman, so pregnant women are advised not to use Brincidofovir.

Acetylcysteine: Serum concentration of Brincidofovir may be increased when it is combined with Acetylcysteine ​​Aminohippuric acid: Serum concentration of Brincidofovir may be increased when it is combined with Aminohippuric acid Amprenavir: Blood concentration The clearance of Brincidofovir may be increased when it is combined with Amprenavir. Apalutamide: The excretion of Brincidofovir may be increased when combined with Apalutamide. Asunaprevir: The serum concentration of Brincidofovir may be increased when it is combined with Asunaprevir Ataluren: Ataluren, Atazanavir, Atorvastatin, Axitinib, Beclomethasone dipropionate: The serum concentration of Brincidofovir may be increased when it is combined. Combination with Beclomethasone dipropionate: OATP 1B1 and 1B3 Inhibitors: If possible, consider alternative drugs that are not OATP1B1 or 1B3 inhibitors. If concomitant use is required, increase monitoring for brincidofovir-associated adverse reactions (elevated transaminases and bilirubin, diarrhea or other gastrointestinal adverse events) and delay OATP1B1 or 1B3 inhibitors at least. at least 3 hours after taking brincidofovir. The above are the uses of the drug Brincidofovir, before using the patient should carefully read the instructions and follow the instructions of the specialist doctor.